DotComs have been extensively studied as therapeutic targets in the context of MLL; where DOT1L activity is augmented to facilitate leukaemia gene expression (84), a role for DotComs in immune cell regulation has not been explored. The gene discussed is KMT2A; the disease is leukemia.